Versant Capital Management Inc Has $245,000 Holdings in GSK plc (NYSE:GSK)

Versant Capital Management Inc increased its stake in GSK plc (NYSE:GSK - Free Report) by 7,077.3% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,316 shares of the pharmaceutical company's stock after purchasing an additional 6,228 shares during the period. Versant Capital Management Inc's holdings in GSK were worth $245,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Indiana Trust & Investment Management Co boosted its stake in shares of GSK by 200.0% in the 4th quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company's stock valued at $25,000 after purchasing an additional 500 shares during the last quarter. Crews Bank & Trust bought a new position in GSK in the fourth quarter valued at approximately $26,000. Sierra Ocean LLC acquired a new stake in GSK during the 4th quarter worth $32,000. Parkside Financial Bank & Trust raised its position in shares of GSK by 470.1% during the 4th quarter. Parkside Financial Bank & Trust now owns 992 shares of the pharmaceutical company's stock valued at $34,000 after acquiring an additional 818 shares during the last quarter. Finally, Golden State Wealth Management LLC acquired a new position in shares of GSK in the 4th quarter valued at $38,000. 15.74% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

GSK has been the subject of a number of recent analyst reports. Morgan Stanley began coverage on GSK in a report on Wednesday, February 12th. They issued an "equal weight" rating for the company. Wall Street Zen cut GSK from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. Hsbc Global Res raised shares of GSK to a "strong sell" rating in a research note on Monday, April 28th. Berenberg Bank reiterated a "hold" rating on shares of GSK in a report on Tuesday. Finally, BNP Paribas started coverage on shares of GSK in a report on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 price target for the company. One analyst has rated the stock with a sell rating, nine have issued a hold rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, GSK currently has an average rating of "Hold" and an average price target of $37.38.

GSK Price Performance

NYSE:GSK traded up $0.46 during mid-day trading on Wednesday, reaching $40.92. The stock had a trading volume of 1,529,524 shares, compared to its average volume of 4,833,654. GSK plc has a 12 month low of $31.72 and a 12 month high of $44.67. The stock has a market capitalization of $84.43 billion, a PE ratio of 25.74, a P/E/G ratio of 1.12 and a beta of 0.51. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. The stock has a 50-day simple moving average of $37.44 and a two-hundred day simple moving average of $36.25.

GSK (NYSE:GSK - Get Free Report) last issued its earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share for the quarter, beating analysts' consensus estimates of $1.08 by $0.05. The firm had revenue of $10.06 billion for the quarter, compared to the consensus estimate of $7.52 billion. GSK had a return on equity of 48.59% and a net margin of 8.13%. The company's revenue was up 2.1% compared to the same quarter last year. During the same quarter last year, the business posted $0.43 EPS. On average, equities analysts anticipate that GSK plc will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 10th. Investors of record on Friday, May 16th will be paid a $0.4216 dividend. This is a positive change from GSK's previous quarterly dividend of $0.39. This represents a $1.69 dividend on an annualized basis and a dividend yield of 4.12%. The ex-dividend date of this dividend is Friday, May 16th. GSK's payout ratio is currently 86.60%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.